2012
DOI: 10.1111/j.1440-1843.2012.02274.x
|View full text |Cite
|
Sign up to set email alerts
|

Autoimmune pulmonary alveolar proteinosis: Treatment options in year 2013

Abstract: Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by accumulation of a periodic acid Schiff (PAS)-positive eosinophilic material in the distal airways. For decades, the standard treatment of PAP has been whole lung lavage (WLL), where large quantities of saline are instilled into the lungs to remove the proteinaceous material. However, not all patients respond to this treatment. Thus, new treatment modalities, such as subcutaneous or inhaled granulocyte macrophage colony-stimulating fac… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
54
0
19

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 66 publications
(73 citation statements)
references
References 79 publications
(167 reference statements)
0
54
0
19
Order By: Relevance
“…Lung transplantation and plasmapheresis have been performed and rituximab has been administered in selected cases, but further studies are needed on this issue. The rate of 5-year survival is 74.7%±8.1% in PAP patients (7). Spontaneous progression can be observed in the disease.…”
Section: Pulmonary Alveolar Proteinosismentioning
confidence: 85%
See 1 more Smart Citation
“…Lung transplantation and plasmapheresis have been performed and rituximab has been administered in selected cases, but further studies are needed on this issue. The rate of 5-year survival is 74.7%±8.1% in PAP patients (7). Spontaneous progression can be observed in the disease.…”
Section: Pulmonary Alveolar Proteinosismentioning
confidence: 85%
“…Because our patient was asymptomatic and no gas exchange abnormality was observed, we decided to follow up the patient, and TPL was not performed. The use of GM-CSF (inhaler or subcutaneous) in PAP patients is recommended for patients with progressive course of the disease despite TPL treatment (7). Lung transplantation and plasmapheresis have been performed and rituximab has been administered in selected cases, but further studies are needed on this issue.…”
Section: Pulmonary Alveolar Proteinosismentioning
confidence: 99%
“…Secondary PAP is diagnosed based on a history of exposures such as hematologic diseases or inhalation agents and the lack of antibodies, while congenital PAP rests on genetic testing [1]. The standard treatment of autoimmune PAP is WLL, where the excess surfactant is mechanically cleansed from the lungs [6]. Reiterated treatments are often necessary.…”
Section: Discussionmentioning
confidence: 99%
“…Rituximab (an anti-CD 20 B-cell antibody) has been reported with beneficial clinical outcome due to improved DLCO, CT scan, symptoms, and in case reports corresponding a reduced number of GM-CSF antibodies. In the case of progressive terminal respiratory failure despite of attempts with the mentioned treatment modalities, lung transplantation may be the last choice of treatment, but has only been described in a few cases [6]. …”
Section: Discussionmentioning
confidence: 99%
“…However, not all patients respond to this treatment. Based on the current literature, a stepwise treatment plan is suggested starting with WLL, continuing to inhaled GM-CSF, and then to rituximab if the former treatment regimes are unsuccessful (Leth et al, 2013;Yamamoto et al, 2008). Some authors think that the whole-lung lavage is a safe and effective palliative procedure in pulmonary alveolar proteinosis and in the treatment of patients with pulmonary disease, such as cystic fibrosis or asthma, in which filling of the lung acini by liquid or solid material impairs oxygenation of the pulmonary capillary blood (Lippmann et al, 1977).…”
Section: Whole Lung Lavagementioning
confidence: 99%